GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OSTO:XVIVO) » Definitions » ROC (Joel Greenblatt) %

Xvivo Perfusion AB (OSTO:XVIVO) ROC (Joel Greenblatt) % : 31.54% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xvivo Perfusion AB ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Xvivo Perfusion AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 31.54%.

The historical rank and industry rank for Xvivo Perfusion AB's ROC (Joel Greenblatt) % or its related term are showing as below:

OSTO:XVIVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -88.33   Med: 17.31   Max: 51.03
Current: 41.5

During the past 12 years, Xvivo Perfusion AB's highest ROC (Joel Greenblatt) % was 51.03%. The lowest was -88.33%. And the median was 17.31%.

OSTO:XVIVO's ROC (Joel Greenblatt) % is ranked better than
86.82% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs OSTO:XVIVO: 41.50

Xvivo Perfusion AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Xvivo Perfusion AB ROC (Joel Greenblatt) % Historical Data

The historical data trend for Xvivo Perfusion AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB ROC (Joel Greenblatt) % Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.48 -88.33 11.03 22.76 51.03

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.32 5.63 9.26 129.48 31.54

Competitive Comparison of Xvivo Perfusion AB's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Xvivo Perfusion AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's ROC (Joel Greenblatt) % falls into.



Xvivo Perfusion AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(98.127 + 141.604 + 27.85) - (47.924 + 0 + 76.296)
=143.361

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(168.603 + 150.961 + -1.1368683772162E-13) - (0 + 0 + 188.804)
=130.76

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Xvivo Perfusion AB for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=75.972/( ( (97.552 + max(143.361, 0)) + (110.136 + max(130.76, 0)) )/ 2 )
=75.972/( ( 240.913 + 240.896 )/ 2 )
=75.972/240.9045
=31.54 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (OSTO:XVIVO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Xvivo Perfusion AB ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (OSTO:XVIVO) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (OSTO:XVIVO) Headlines

No Headlines